半胱氨酰白三烯受体拮抗剂在Guidelines中地位(修改后).pptVIP

下载本文档

0
0
约1.96万字
约 54页
2018-12-21 发布于浙江
举报
版权申诉

半胱氨酰白三烯受体拮抗剂在Guidelines中地位(修改后).ppt

1、本文档共54页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

* * TABLE II. Outcome frequencies in the 12 months after dispensing the controller medication in a subset of subjects who were continuously enrolled for the 12 months after controller medication dispensing: the number of subjects who experienced 1 or more ED visits, hospitalizations, oral courses of oral corticosteroids In subjects who metcriteria for continuous enrollment, 21% of patients in TennCare Medicaid who filled an ICS experienced an exacerbation compared with 17% of patients who filled an ICS-LABA or 14% who filled an LTRA (P 0 .001). * * Figure 3. Algorithm of preventive pharmacologic treatment for asthma in children 2 years of age Regular controller therapy. The main goal of regular controller therapy should be to reduce bronchial inflammation. 常规控制剂治疗的主要目标是减少气道炎症 LTRA? An alternative first-line treatment for persistent asthma. 持续性哮喘可选的一线治疗? Evidence supports use of oral montelukast as an initial controller therapy for mild asthma in children (153), as it provides bronchoprotection (154), and reduces airway inflammation as measured by nitric oxide levels in some preschool children with allergic asthma (155, 156). 有证据显示口服孟鲁司特是儿童轻度哮喘的首选控制剂，它可提供气道保护的作用，在学龄前过敏性哮喘的儿童中通过检测一氧化氮证实其可以减少气道炎症? Younger age (10 years) and high levels of urinary leukotrienes predict a favorable response to LTRA(149). 较小的年龄（10岁）和高水平的尿白三烯支持使用LTRA治疗? A therapy for patients who cannot or will not use ICS. 患者不能或不愿意使用ICS? Useful also as add-on therapy to ICS as their mechanisms of action are different and complementary(157). 因为作用机制不同，联合ICS治疗可互补? Suggested as treatment for viral-induced wheeze and to reduce the frequency of exacerbations in young children aged 2–5 years (158, 159). 治疗2-5岁患儿的病毒诱发喘息可以减少急性发作频率? Benefit has been shown in children as young as 6 months of age (156, 160). 对于6个月患儿也显示有益处 * * * * * * * * Figure 4 The stepwise approach to asthma treatment in childhood aims at disease control. Reliever medication should be used at any level of severity/control, if symptoms app